SEC Company Response from Black Diamond Therapeutics, (BDTX) — Jan 27, 2020
Black Diamond Therapeutics, Inc.
Date: Jan. 27, 2020 · CIK: 0001701541 · Accession: 0001193125-20-015329
AI Filing Summary & Sentiment
File numbers found in text: 333-235789
Letter
VIA EDGAR Division of Corporation Finance AccelerationRequest for Registration Statement on Form S-1 File No. 333-235789 Requested Date: January 29, 2020 Requested Time: 4:00 p.m. Eastern Standard Time
Dear Ms. Bednarowski and Mr. King:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Black Diamond Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to January 29, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Marishka DeToy at (617) 570-1926. We also respectfully request that a copy of the written order from the Securities and Exchange Commission (the “Commission”) verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Marishka DeToy, by facsimile to (617) 321-4360.
[Remainder of page left intentionally blank]
If you have any questions regarding this request, please contact Marishka DeToy of Goodwin Procter LLP at (617) 570-1926.
Sincerely,
BLACK DIAMOND THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP VIA EDGAR January 27, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance Mail Stop 4561 100 F Street, N.E. Washington, D.C. 20549 Attn: Sonia Bednarowski Dietrich King Re: Black Diamond Therapeutics, Inc. AccelerationRequest for Registration Statement on Form S-1 File No. 333-235789 Requested Date: January 29, 2020 Requested Time: 4:00 p.m. Eastern Standard Time Dear Ms. Bednarowski and Mr. King: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Black Diamond Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to January 29, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Marishka DeToy at (617) 570-1926. We also respectfully request that a copy of the written order from the Securities and Exchange Commission (the “Commission”) verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Marishka DeToy, by facsimile to (617) 321-4360. [Remainder of page left intentionally blank] If you have any questions regarding this request, please contact Marishka DeToy of Goodwin Procter LLP at (617) 570-1926. Sincerely, BLACK DIAMOND THERAPEUTICS, INC. /s/ David M. Epstein David M. Epstein President and Chief Executive Officer cc: Thomas Leggett, Chief Financial Officer, Black Diamond Therapeutics, Inc. Robert E. Puopolo, Esq., Goodwin Procter LLP